

cynata
therapeutics



A Next Generation Stem Cell Company

Dr. Ross Macdonald, CEO
Cynata Therapeutics Limited

Singapore + Hong Kong Biotech Invest, March 2017

Important Information

This presentation has been prepared by Cynata Therapeutics Limited. (“Cynata” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Cynata Therapeutics, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Cynata Therapeutics and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Cynata Therapeutics is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Cynata Therapeutics securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Cynata Therapeutics, its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Cynata Therapeutics does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

The distribution of this presentation may be restricted by law and you should observe any such restrictions.

Forward looking statements

This presentation contains certain forward looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Cynata to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which Cynata will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Cynata and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

Key Facts

Cynata Therapeutics Ltd is an Australian stem cell and regenerative medicine company.



ASX CODE
CYP



COMMENCED OPERATIONS
November 2013



MARKET CAP (17 March 17)
A\$ 50m



SHARES ON ISSUE
90m¹



CASH
\$ 3.9m as at 31 Dec 2016
PLUS \$10m raised in Jan 2017 via placement and FUJIFILM strategic partnership



AVERAGE MONTHLY NET CASH BURN
A\$470k (gross)



NUMBER OF SHAREHOLDERS
~1900; FUJIFILM ~9%


¹ Plus 10.8m Options: 3.7m Jul 20 @ AUD \$1.00; plus 5m 27 Sep 18 unlisted AUD \$0.40 restricted options, 50% to each of S Washer and R Macdonald

Investment Highlights **Summary**

- **Only company** in the world that can mass-produce therapeutic mesenchymal stem cells (MSCs) at a consistent quality and affordable cost without multiple donors
- Cynata's Cymerus™ technology **overcomes the challenges inherent in first generation production** methods and the regulatory hurdles by industrialising the production of MSCs
- **Strong data in pre-clinical studies** for the treatment of asthma, heart attack, GvHD (Graft-versus-Host disease) and critical limb ischaemia
- **Regenerative medicine market expected to grow to US\$170bn** by 2020* and an attractive investment area for biopharmaceutical companies, e.g. Astellas, J&J and Fujifilm
- **Licensing-driven business model with near term revenue** and commercial partnerships in place with Fujifilm and apceth GmbH & Co KG
- **Experienced management** team and strong academic partnerships
- **Value-accretive news flow** expected in near term

*Source: Grand View Research Report published Sept 2015
<http://www.grandviewresearch.com/industry-analysis/stem-cells-market>

Cynata Milestones



About Cynata's Technology




(animation)

Mesenchymal Stem Cell (MSC) Therapeutics

~652* open clinical studies using MSCs including:








Annual Market Value (\$US)




- Profound legislative changes to expedite stem cell therapies (Japan)
- Massive government investment e.g. California (CIRM): US\$3bn
- Significant potential applications including spinal cord injuries, stroke, Alzheimer's disease, Parkinson's disease, diabetes, heart attack

1. US Centre for Disease Control and Prevention
2. GBI Research
3. GBI Research
4. BCC Research
5. Research and Markets
*www.clinicaltrials.gov

Cynata's Therapeutic Product Pipeline

Therapeutic Area	Indication	Preclinical	Phase 1	Comments
Immunological Disorders	Graft versus host disease			World first trial
	Organ transplant rejection			
Pulmonary Disorders	Pulmonary fibrosis			
	Asthma			Compelling pre-clinical data
Circulatory Disorders	Critical limb ischaemia			Compelling pre-clinical data
	Myocardial Infarction (heart attack)			Compelling pre-clinical data
Cancer	Glioblastoma (brain tumour)			

Cynata's Cymerus™ : Outstanding Pedigree



Inventors include: Dr James Thomson

- In 1998 derived the first human embryonic stem cell line
- 2007 derived human induced pluripotent stem cells



...and Prof Igor Slukvin, co-founder and author of >70 publications in the stem cell field; #3 shareholder



In-licensed intellectual property includes several issued U.S. patents as well as a broad estate of issued and pending patents

BUSINESS MODEL: Commercial Partnerships

Capital efficient license-driven strategy

Revenue Streams

- License payments

Licensing Cymerus™ platform to big pharma/biotech

- Milestone payments

From partners as products progress

- Royalties

From partner revenue of marketed products

Already secured commercial agreements with global cell and regenerative medicine companies

FUJIFILM

- License option agreement: equity (9%) + upfronts + milestones (potential \$60m+) and royalties; development costs
- Strategic investor; brings substantial resources

apceth
applied cell therapy

- License option agreement
- Upfronts, milestones and royalties
- Opens new commercial opportunities for modified MSCs

High Impact Newsflow

What's Next?

Commence WORLD-FIRST Phase 1 trial

Formal interaction with FDA

Progress licence option agreement with apceth

Additional commercial + development
partnerships

Continued success of MSC-based therapeutics



Thank you for your attention

Cynata Therapeutics Limited
Suite 1,
1233 High Street,
Armadale, Victoria 3143



Contact details:

✉ ross.macdonald@cynata.com

☎ +61 (0) 412 119343

🌐 www.cynata.com

